Resources Antibody Industry Trends Biointron Insights: Antibody Industry Report (Q2 2024 Insights, Trends & Analysis)

Biointron Insights: Antibody Industry Report (Q2 2024 Insights, Trends & Analysis)

Biointron 2024-07-01

Biointron Q2 2024 Insights

This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year:

  1. Tarlatamab (Imdelltra), a bispecific antibody treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

  2. Seniprutug (Tribuvia), a monoclonal antibody drug for ankylosing spondylitis, also known as axial spondyloarthritis or Bechterew-Strümpell syndrome.

This quarter saw notable progress in antibody drug discovery with machine learning, particularly with the advancements in generative AI, reducing development timelines and increasing the efficiency of targeting complex diseases. We delve into three companies to watch who are using AI for antibody drug discovery.

Q2 2024 witnessed major deals and acquisitions of up to $3 billion USD in value. Investment in antibodies is also continuing, with startup launches of up to $1 billion USD focused on AI, diseases such as obesity, and next-generation formats like antibody-peptide conjugates (APCs). We highlight three APCs currently in development, as well as weight-loss antibody medications.

There are several exciting antibodies to watch in Q3 which are either in regulatory review or in late-stage clinical trials. These antibodies range from those treating cancers to COVID-19 and skin diseases.

Register now for a free download of the report!


Register to access the full report produced by Biointron

*
*
*
*
*

Subscribe to our Antibody Industry Trends

Recent Antibody Industry Trends

The approval of Eli Lilly’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements in the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology.

Blood disorders, including anemias, coagulopathies, leukemias, lymphomas, and thrombocytopenias, disrupt the normal functioning of blood components. Antibody therapeutics, such as monoclonal antibodies (mAbs), have transformed treatment approaches by offering targeted, high-specificity interventions.

Over four years have passed since the first SARS-CoV-2 outbreak, and scientific advancements have reshaped our understanding of immunity and virus dynamics.

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.